IPO and Financial Overview - Aimfinity completed its IPO on April 28, 2022, raising gross proceeds of $80.5 million from the sale of 8,050,000 units at $10.00 per unit[145]. - The Company incurred $5,117,607 in transaction costs related to the IPO, including $1,610,000 in underwriting fees and $2,817,500 in deferred underwriting fees[180]. - The underwriters received a cash underwriting discount of $1,610,000 at the closing of the IPO[192]. - The deferred underwriting commission of $2,817,500 will be payable upon the consummation of an initial business combination[192]. Business Combination and Mergers - Aimfinity entered into a merger agreement with Docter Inc. on October 13, 2023, which will result in PubCo becoming a publicly traded company[148]. - The board of directors of PubCo will consist of five directors post-merger, with three designated by Docter and two by the Sponsor[153]. - Aimfinity has no assurance that its plans for an initial business combination will be successful[144]. - The Company approved the Third Charter Amendment allowing an extension of the Combination Deadline to October 28, 2025, with a total of $502,414.2 deposited for nine one-month extensions[159]. - The Fourth Charter Amendment allows for an extension of the Combination Deadline to July 28, 2025, with $500 required for each one-month extension[161]. Shareholder Actions and Redemptions - As of the First EGM, approximately 50.9% of AIMA New Units were redeemed, resulting in the cancellation of 4,076,118 units[155]. - At the Second EGM, 21.7% of AIMA New Units were redeemed, leading to approximately $9.68 million being distributed from the Trust Account[158]. - Approximately 1,996,522 AIMA New Units, or about 64.2% of the public AIMA New Units, were redeemed, resulting in $23,778,577 distributed from the Trust Account[160]. - A total of 572,989 AIMA New Units, or about 51.3% of the public AIMA New Units, were redeemed during the Fourth EGM, leading to $7,357,178.76 distributed from the Trust Account[162]. - Up to 2,500,000 additional shares may be issued to Docter stockholders as contingent post-closing earnout consideration based on device sales targets[151]. - 1,000,000 earnout shares will be issued if PubCo sells at least 30,000 devices in fiscal year 2024, and 1,500,000 shares for 40,000 devices in fiscal year 2025[151]. Financial Position and Operations - The company has incurred losses since inception and currently has no revenue, relying on the sale of securities and loans for funding[147]. - The Company held $14,294,569 in the Trust Account as of September 30, 2025, invested in U.S. Treasury Securities, intended for the Initial Business Combination[181]. - The Company reported a working capital deficiency of $2,785,815 as of September 30, 2025[187]. - Management has raised substantial doubt about the Company's ability to continue as a going concern due to the inability to complete an initial business combination by the Combination Deadline[188]. - The Company has not generated any operating revenues to date, with activities focused on preparing for the IPO and identifying a target for the Initial Business Combination[177]. - The Company plans to use funds held outside the Trust Account primarily for identifying and evaluating target businesses and related due diligence[182]. - As of September 30, 2025, the Company had borrowings of $1,539,134 under working capital loans[186]. - The Company issued promissory notes totaling $2,500,000 for working capital, with $1,539,134 drawn as of September 30, 2025[169]. Accounting and Regulatory Matters - The Company is evaluating the impact of adopting ASU No. 2024-03 on its financial statements, which requires expanded expense disclosures[195]. - Management does not believe that any recently issued accounting standards will have a material effect on the Company's financial statements[196]. - The Company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[197]. - The Company has no off-balance sheet financing arrangements as of September 30, 2025[189].

IPO and Financial Overview - Aimfinity Investment Corp. I completed its IPO on April 28, 2022, raising gross proceeds of $80.5 million from the sale of 8,050,000 units at $10.00 per unit[136]. - The company has incurred losses since inception and currently has no revenue, relying on the sale of securities and loans for funding[138]. - Following the IPO, 4,076,118 AIMA New Units, or approximately 50.9% of the total, were redeemed by shareholders[147]. - The Company has $13,671,304 held in the Trust Account, which is intended to be used for completing the Initial Business Combination[167]. - An aggregate of approximately $23,778,577 was distributed from the Trust Account to redeeming Public Shareholders, with 1,996,522 AIMA New Units submitted for redemption, representing about 64.2% of the public units[151]. - The Company incurred $5,117,607 in transaction costs related to the IPO, including $1,610,000 in underwriting fees[166]. - The underwriters received a cash underwriting discount of $0.20 per Public Unit, totaling $1,610,000 at the closing of the IPO[178]. - A deferred fee of $0.35 per Public Unit, approximately $2,817,500 in total, will be payable upon the consummation of an initial business combination[178]. Merger and Business Combination - On October 13, 2023, Aimfinity entered into a merger agreement with Docter Inc., which will result in Docter becoming a wholly owned subsidiary of the newly formed PubCo[139]. - Up to 2.5 million additional PubCo Ordinary Shares may be issued to Docter Stockholders as contingent post-closing earnout consideration based on sales performance[142]. - The merger agreement includes provisions for earnout shares contingent on sales of at least 30,000 devices in fiscal year 2024 and 40,000 devices in fiscal year 2025[144]. - The merger agreement stipulates that the board of directors of PubCo will consist of five directors, with a new composition following the business combination[143]. - The Company entered into an Exchange Agreement to convert approximately $1.5 million of outstanding promissory notes into 150,000 private units in connection with the Docter Business Combination[160]. Financial Performance and Projections - As of March 31, 2025, the Company had a working capital deficiency of $3,715,292 and cash of $4,895[173]. - For the three months ended March 31, 2025, the Company reported a net income of $64,931, with interest income of $342,182 offset by operating costs of $277,251[164]. - The Company has not generated any revenues to date and does not expect to do so until after the completion of the Initial Business Combination[163]. Compliance and Regulatory Matters - A second extraordinary general meeting was held on April 23, 2024, where shareholders approved an extension of the deadline to consummate an initial business combination to January 28, 2025[148]. - The Company has the option to extend the deadline for consummating an initial business combination up to nine times, each by an additional one-month period[146]. - The Company received a notice from Nasdaq regarding non-compliance, leading to a transfer of listing to the OTC Market effective May 5, 2025[161]. Accounting and Reporting Standards - The company is evaluating the impact of adopting ASU No. 2024-03, which requires expanded income statement expense disclosures, effective for fiscal years commencing after December 15, 2026[180]. - Management does not anticipate that recently issued accounting standards will have a material effect on the company's financial statements[181]. - The company qualifies as a smaller reporting company and is not required to provide certain market risk disclosures[182].

IPO and Financial Proceeds - The company completed its IPO on April 28, 2022, raising gross proceeds of $80.5 million from the sale of 8,050,000 units at $10.00 per unit[17]. - A total of $82.11 million from the IPO and private placement was deposited into a trust account for the benefit of public shareholders[17]. - Aimfinity completed its IPO on April 28, 2022, raising gross proceeds of $80,500,000 from the sale of 8,050,000 Public Units[133]. - A total of $765,000 was deposited into the Trust Account for nine First EGM Extensions, extending the Combination Deadline from July 28, 2023, to April 28, 2024[209]. - From April 2024 to December 2024, $540,000 was deposited into the Trust Account for nine Second EGM Extensions, extending the Combination Deadline from April 28, 2024, to January 28, 2025[212]. - A total of $167,471 was deposited into the Trust Account for one Current Monthly Extension, extending the Combination Deadline from January 28, 2025, to April 28, 2025[216]. Business Operations and Strategy - The company has not engaged in any operations or generated any revenue to date, classifying it as a "shell company" under the Securities Exchange Act[16]. - The company has focused on identifying unique business concepts in technology, hospitality, and consumer services sectors, excluding targets headquartered or primarily operating in China[20]. - Aimfinity currently has no revenue and has incurred losses since inception, relying on the sale of securities and loans to fund operations[106]. - The company intends to effectuate its initial business combination using cash from the IPO proceeds and may incur significant costs in pursuit of acquisition plans[103]. - The Company anticipates the amount in the Trust Account to be $10.20 per public share at the time of the initial business combination[63]. - Public shareholders will have the opportunity to redeem their Class A ordinary shares for cash upon completion of the initial business combination, with the redemption price based on the Trust Account balance[63]. Management and Governance - As of March 17, 2023, all directors and officers resigned, and I-Fa Chang was appointed as the sole director and CEO[22]. - The company has two executive officers, the CEO and CFO, who are not obligated to devote specific hours to the company's affairs until the initial business combination is completed[80]. - The board of directors consists of five members, with directors serving a two-year term and vacancies filled by a majority vote of remaining directors[176]. - The audit committee consists of three independent members, with Kevin Vassily serving as the Chair, and all members are financially literate[180]. - The company has established an audit committee responsible for monitoring compliance with applicable laws and regulations, and overseeing the independent registered public accounting firm[183]. - The Company engaged MaloneBailey, LLP as its independent registered public accounting firm effective May 1, 2023, dismissing Marcum LLP on the same date[155]. Shareholder Actions and Rights - A total of 4,076,118 public shares were redeemed during the first extraordinary general meeting, resulting in their cancellation[27]. - 860,884 public shares were redeemed during the second extraordinary general meeting, leading to their cancellation[34]. - Initial shareholders have agreed to waive their redemption rights concerning any founder shares and public shares in connection with the initial business combination[67]. - The Company will limit public shareholders from redeeming more than 15% of the shares sold in the IPO without prior consent to discourage large block accumulations[68]. - The Sponsor has agreed not to redeem any founder shares or public shares in connection with a shareholder vote for the proposed initial business combination[196]. Financial Health and Risks - The company has no operating history and no revenues, raising substantial doubt about its ability to continue as a "going concern"[81]. - The company faces intense competition from other entities with similar business objectives, which may limit its ability to acquire larger target businesses[78]. - The company faces risks related to competition for attractive acquisition targets, which may increase costs or hinder the ability to find a suitable target[83]. - Aimfinity's management has raised substantial doubt about the company's ability to continue as a going concern if it cannot complete a business combination within the specified period[143]. - The company had cash of $4,895 and a working capital deficiency of $3,270,570 as of December 31, 2024, with $1,202,852 in borrowings under working capital loans[142]. Internal Controls and Compliance - Management assessed the effectiveness of internal controls over financial reporting as of December 31, 2024, and determined that they were not effective due to material weaknesses[164]. - The Company plans to implement remediation steps to improve internal controls, including enhancing board composition and consulting third-party professionals[165]. - There were no changes in internal control over financial reporting that materially affected the Company's controls during the reporting period[167]. - The company has adopted a Clawback Policy on November 29, 2023, allowing the Compensation Committee to require reimbursement of erroneously awarded compensation due to accounting restatements[184]. Mergers and Acquisitions - The Docter Business Combination involves merging with Docter Inc. and is expected to result in 6,000,000 PubCo Ordinary Shares valued at $60,000,000[47]. - Aimfinity has entered into a merger agreement with Docter Inc., which will result in Aimfinity being merged into a newly formed publicly traded company, PubCo[107]. - The merger agreement allows for nine one-month extensions, with a payment of $0.05 per share for each extension, potentially extending the deadline to October 28, 2025[38]. - The board of directors of PubCo will consist of five directors post-merger, with three designated by Docter and two by the Sponsor[112]. - Up to 2,500,000 additional PubCo Ordinary Shares may be issued as contingent post-closing earnout consideration based on device sales[48][50]. Audit and Financial Reporting - Marcum's audit report for the fiscal year ended December 31, 2022, did not contain an adverse opinion, but expressed uncertainty about the Company's ability to continue as a going concern[156]. - Aimfinity's audit committee reviews all payments made to its Sponsor, officers, directors, or their affiliates on a quarterly basis[200]. - The Company has until January 28, 2025, to consummate an Initial Business Combination, with potential extensions up to October 28, 2025[213].

IPO and Fundraising - The company completed its IPO on April 28, 2022, raising gross proceeds of $80.5 million from the sale of 8,050,000 units at $10.00 per unit[130]. - A private placement generated an additional $4.92 million from the sale of 492,000 units at the same price, totaling net proceeds of $82.11 million deposited in a trust account[130]. - The company incurred $5,117,607 in transaction costs related to the IPO, including $1,610,000 in underwriting fees and $2,817,500 in deferred underwriting fees[155]. - The company issued promissory notes totaling up to $2,500,000 to I-Fa Chang for working capital, which are non-interest bearing and unsecured[159][160][161]. Business Combination - On October 13, 2023, the company entered into a Business Combination Agreement with Docter Inc., aiming to merge and create a publicly traded entity[133]. - The Business Combination will involve the issuance of 6 million PubCo Ordinary Shares valued at $60 million, with potential additional earnout shares based on future sales performance[135][136]. - The company has the option to extend the deadline for completing the initial business combination up to nine months, with a total of $765,000 deposited for extensions[140]. - The second extraordinary general meeting approved an extension to January 28, 2025, with a payment structure of $60,000 or $0.035 per public share for each one-month extension[141][142]. - The company has made six payments for the second extension, totaling $360,000, to extend the combination deadline[142]. - The company has entered into a backstop agreement to ensure net tangible assets of at least $5,000,001 upon closing of the Business Combination[150]. - The company has no assurance that its plans for the Initial Business Combination will be successful, reflecting inherent risks and uncertainties[129]. Financial Performance - For the three months ended September 30, 2024, the company reported a net income of $24,789, with interest income of $464,528 and operating costs of $439,739[152]. - For the nine months ended September 30, 2024, the company had a net income of $902,163, consisting of interest income of $1,603,118 and operating costs of $700,955[153]. - As of September 30, 2024, the company held $36,327,836 in the Trust Account, which is invested in money market funds and U.S. Treasury Securities[156]. - As of September 30, 2024, the company had a working capital deficiency of $2,972,900 and cash of $4,895[163]. - The company has not generated any operating revenues to date and does not expect to do so until after completing its Initial Business Combination[151]. Going Concern - Management has raised substantial doubt about the company's ability to continue as a going concern if the Initial Business Combination is not completed by the Combination Deadline[164]. - The company has no off-balance sheet financing arrangements as of September 30, 2024[165].

IPO and Fundraising - The company completed its IPO on April 28, 2022, raising gross proceeds of $80.5 million from the sale of 8,050,000 units at $10.00 per unit[124]. - A private placement generated an additional $4.92 million from the sale of 492,000 units at the same price, totaling net proceeds of $82.11 million deposited in a trust account[124]. - The company incurred $5,117,607 in transaction costs related to the IPO, including $1,610,000 in underwriting fees and $2,817,500 in deferred underwriting fees[148]. Business Combination - On October 13, 2023, the company entered into a Business Combination Agreement with Docter Inc., which will result in the company being merged into a newly formed subsidiary[127]. - The Business Combination will involve the issuance of 6,000,000 PubCo Ordinary Shares valued at $60 million, with potential additional earnout shares based on future sales performance[129][130]. - The company has extended the deadline to consummate an initial business combination to April 28, 2024, with provisions for up to nine one-month extensions[134]. - The first charter amendment allowed for a total of $765,000 to be deposited for extensions, with each extension costing $85,000 or $0.04 per public share[134]. - The second charter amendment allows for extensions until January 28, 2025, with a reduced cost of $60,000 or $0.035 per public share for each one-month extension[135]. - As of the latest update, the company has made three payments of $60,000 each for the second charter amendment extensions, extending the deadline to August 28, 2024[136]. - The company has issued unsecured promissory notes for the payments made for the extensions, which are payable upon the consummation of the initial business combination or at the maturity date[138]. Financial Performance - For the three months ended June 30, 2024, the company reported a net income of $438,510, consisting of interest income of $570,206 on investments held in the Trust Account, offset by operating costs of $131,696[145]. - For the six months ended June 30, 2024, the company had a net income of $877,374, with interest income of $1,138,590 on investments held in the Trust Account, offset by operating costs of $261,216[146]. - As of June 30, 2024, the company held $35,683,308 in the Trust Account, invested in money market funds and U.S. Treasury Securities[149]. - As of June 30, 2024, the company had a working capital deficiency of $2,353,161 and cash of $4,895[155]. Operational Status - The company has incurred losses since inception and currently has no revenue, relying on the sale of securities and loans to fund operations[126]. - The company has not engaged in any operations or generated revenues since its inception on July 26, 2021, and does not expect to generate operating revenues until after completing its Initial Business Combination[144]. - Management has raised substantial doubt about the company's ability to continue as a going concern if it cannot complete an Initial Business Combination by the Combination Deadline[156]. - The company intends to use funds held outside the Trust Account primarily for identifying and evaluating target businesses and performing due diligence[150]. - The company has no off-balance sheet financing arrangements as of June 30, 2024[157]. Debt and Financing - The company issued a promissory note to I-Fa Chang for up to $500,000 to be used for working capital, which is non-interest bearing and due upon the completion of the Initial Business Combination or liquidation[152].

IPO and Fundraising - The company completed its IPO on April 28, 2022, raising gross proceeds of $80.5 million from the sale of 8,050,000 units at $10.00 per unit[124]. - A private placement generated an additional $4.92 million from the sale of 492,000 units at $10.00 per unit, totaling net proceeds of $82.11 million deposited in a trust account[124]. - The company incurred $5,117,607 in transaction costs related to the IPO, including $1,610,000 in underwriting fees and $2,817,500 in deferred underwriting fees[152]. Business Combination - On October 13, 2023, the company entered into a Business Combination Agreement with Docter Inc., which will result in the company being merged into a newly formed subsidiary[127]. - The Business Combination will involve the issuance of 6,000,000 PubCo Ordinary Shares valued at $60 million, with potential additional earnout shares based on future sales performance[129][130]. - The company has extended its deadline to complete an Initial Business Combination to April 28, 2024, with the possibility of further extensions until January 28, 2025[131][139]. - A total of $765,000 was deposited for nine one-month extensions to extend the Combination Deadline from July 28, 2023, to April 28, 2024[138]. Financial Performance - For the three months ended March 31, 2024, the company reported a net income of $438,864, consisting of interest income of $568,384 on investments held in the Trust Account, offset by operating costs of $129,520[150]. - As of March 31, 2024, the company held $44,618,047 in the Trust Account, which is invested in money market funds and U.S. Treasury Securities[153]. - The company has a working capital deficiency of $2,041,465 as of March 31, 2024, with cash of only $3,977[159]. - The company has drawn $816,437 under working capital loans as of March 31, 2024, with no balance repaid to date[148]. - The company has not generated any revenues to date and does not expect to do so until after completing its Initial Business Combination[149]. Going Concern and Financial Position - The company has substantial doubt about its ability to continue as a going concern if it cannot complete an Initial Business Combination by the Combination Deadline[160]. - The company has no off-balance sheet financing arrangements as of March 31, 2024[161]. - The company intends to use funds held outside the Trust Account primarily for identifying and evaluating target businesses and completing an Initial Business Combination[154]. Shareholder Actions - The company has allowed public shareholders to redeem 860,884 shares, resulting in 3,604,998 Class A ordinary shares remaining post-redemption[134]. Debt and Financing - The company issued a promissory note to I-Fa Chang for up to $500,000 to be used for working capital, which is non-interest bearing and unsecured[147].

IPO and Financial Proceeds - The company completed its IPO on April 28, 2022, raising gross proceeds of $80.5 million from the sale of 8,050,000 units at $10.00 per unit[19]. - A total of $82.11 million from the IPO and private placement was deposited in a trust account for the benefit of public shareholders[19]. - Aimfinity's IPO generated gross proceeds of $80,500,000 from the sale of 8,050,000 Public Units[135]. - A total of $82,110,000 of net proceeds from the IPO and the sale of Private Placement Units was deposited into the Trust Account[109]. - The company incurred $5,117,607 in transaction costs related to its IPO, including $1,610,000 in underwriting fees and $2,817,500 in deferred underwriting fees[137]. Business Combination and Mergers - The company must complete an initial business combination with a total aggregate fair market value of at least 80% of the assets held in the trust account[28]. - The company has until April 28, 2024, to consummate an initial business combination, with the option to extend this period up to nine additional months[42]. - The company entered into a merger agreement with Docter Inc. on October 13, 2023, which will result in Docter becoming a wholly-owned subsidiary of the company[45]. - The merger consideration includes 6,000,000 PubCo Ordinary Shares, valued at $60,000,000, to be distributed to Docter stockholders[50]. - An additional 2,500,000 PubCo Ordinary Shares may be issued as contingent post-closing earnout consideration based on sales performance in fiscal years 2024 and 2025[51]. - Aimfinity intends to use approximately $43,794,663 held in the Trust Account to complete its Business Combination, with funds invested in U.S. Treasury Securities[139]. Shareholder Rights and Redemptions - Public shareholders can redeem their shares regardless of their vote on the proposed transaction[58]. - A public shareholder is restricted from redeeming more than 15% of the shares sold in the IPO without prior consent[59]. - The company intends to conduct redemptions in connection with a shareholder vote unless not required by law or if a tender offer is chosen[56]. - If the company fails to complete a business combination, it will redeem public shares at a price based on the Trust Account balance[63]. - The company anticipates a redemption price of $10.20 per public share upon completion of the initial business combination, based on the amount in the Trust Account[55]. Management and Governance - The management change on March 17, 2023, resulted in the appointment of I-Fa Chang as the sole director and CEO, with Xuedong (Tony) Tian as CFO[24]. - The company has engaged MaloneBailey, LLP as its independent registered public accounting firm effective May 1, 2023, replacing Marcum LLP[156]. - The board of directors consists of five members, with founder shares holders having the right to elect all directors prior to the initial business combination[177]. - The audit committee is composed of independent directors, including Kevin Vassily as the Chair, ensuring compliance with Nasdaq listing standards[181]. - The company has adopted a Clawback Policy on November 29, 2023, allowing the Compensation Committee to require reimbursement of erroneously awarded compensation[185]. Financial Condition and Risks - Aimfinity has incurred losses since inception and currently has no revenue, relying on the sale of securities and loans to fund operations[115]. - The company has raised substantial doubt about its ability to continue as a going concern if it cannot complete a Business Combination within the specified period[145]. - The company currently has two executive officers and does not intend to hire full-time employees before completing the initial business combination[73]. - The current economic downturn and volatility in capital markets may affect the company's ability to secure financing for its business combination[75]. - The company may face increased competition for attractive acquisition targets as the number of special purpose acquisition companies evaluating targets rises[75]. Internal Controls and Compliance - The company reported that its disclosure controls and procedures were not effective as of December 31, 2023, indicating potential weaknesses in financial reporting[161]. - Management assessed the internal control over financial reporting and identified a material weakness due to inadequate segregation of duties and insufficient written policies[165]. - The company plans to enhance its internal controls by increasing board size and consulting third-party professionals for complex accounting applications[166]. - The company has not included an attestation report from its independent registered public accounting firm due to its status as an emerging growth company under the JOBS Act[167]. - The company intends to implement remediation steps to improve internal controls and address identified weaknesses[166].

IPO and Financing - The company completed its IPO on April 28, 2022, raising gross proceeds of $80.5 million from the sale of 8,050,000 units at $10.00 per unit[129]. - A private placement generated an additional $4.92 million from the sale of 492,000 units at the same price, totaling net proceeds of $82.11 million deposited in a trust account[129]. - The company incurred $5,117,607 in transaction costs related to the IPO, including $1,610,000 in underwriting fees and $2,817,500 in deferred underwriting fees[151]. - The company may need to obtain additional financing to complete its Initial Business Combination or due to significant public share redemptions[158]. Business Combination - On October 13, 2023, the company entered into a Business Combination Agreement with Docter Inc., which will result in the company being merged into a newly formed subsidiary[132]. - The Business Combination will involve the issuance of 6,000,000 PubCo Ordinary Shares valued at $60 million, with potential additional earnout shares based on future sales performance[134][135]. - The company has extended the period to consummate an Initial Business Combination to April 28, 2024, allowing for up to nine one-month extensions[138]. - The company has deposited $85,000 into the Trust Account for each monthly extension from July 2023 to October 2023, facilitating the extension of the Initial Business Combination period[142]. Financial Performance - For the three months ended September 30, 2023, the company reported a net income of $540,850, with interest earned on investments in the Trust Account offset by operating costs of $397,927[148]. - For the nine months ended September 30, 2023, the company achieved a net income of $1,860,776, with total operating costs amounting to $844,605[148]. - As of September 30, 2023, the company held $42,978,326 in the Trust Account, primarily invested in U.S. Treasury Securities[153]. - As of September 30, 2023, the company had a working capital deficiency of $894,947 and cash of $5,503[156]. Revenue and Operations - The company has incurred losses since inception and currently has no revenue, relying on securities sales and loans for funding[131]. - The company has not generated any operating revenues to date and does not expect to do so until after completing its initial Business Combination[147]. - The company intends to use funds held outside the Trust Account for identifying and evaluating target businesses and performing due diligence[154]. Tax and Accounting - The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense, with no unrecognized tax benefits or accrued amounts as of September 30, 2023[177]. - The Company is subject to potential examinations by federal and state taxing authorities regarding income taxes, but management does not expect significant changes in unrecognized tax benefits over the next twelve months[179]. - The Company determined that the Cayman Islands is its only major tax jurisdiction[178]. - The Company accounts for income taxes under ASC 740, recognizing deferred tax assets and liabilities for differences between financial statement and tax basis[174]. - ASC 740 requires a valuation allowance when it is more likely than not that deferred tax assets will not be realized[175]. - Management does not anticipate that any recently issued accounting standards will materially affect the Company's financial statements[181]. - The Company is classified as a smaller reporting company and is not required to provide additional market risk disclosures[182]. Financial Instruments - The fair value of the Company's financial instruments approximates the carrying amounts in the balance sheet due to their short-term nature[173]. - The fair value hierarchy includes three levels: Level 1 based on quoted prices in active markets, Level 2 based on quoted prices in inactive markets or other inputs, and Level 3 based on unobservable inputs[176].

IPO and Financial Proceeds - The company completed its IPO on April 28, 2022, raising gross proceeds of $80.5 million from the sale of 8,050,000 units at $10.00 per unit[111]. - The company incurred $5,117,607 in transaction costs related to the IPO, including $1,610,000 in underwriting fees and $2,817,500 in deferred underwriting fees[126]. - The underwriters received a cash underwriting discount of $0.20 per Public Unit, totaling $1,610,000, and a deferred fee of approximately $2,817,500 upon consummation of a business combination[136]. Financial Position and Performance - As of June 30, 2023, the Trust Account held $84,502,266 in money market funds, primarily invested in U.S. Treasury Securities[127]. - For the three months ended June 30, 2023, the company reported a net income of $640,387, primarily from interest earned on investments in the Trust Account[123]. - As of June 30, 2023, the company had cash of $5,169 and a working capital deficiency of $242,020[130]. - The company incurred operating costs of $297,986 and $446,678 for the three and six months ended June 30, 2023, respectively[123]. - The company has not generated any operating revenues to date and does not expect to do so until after completing its initial Business Combination[122]. Business Combination and Future Plans - The company has not selected any Business Combination target and has not initiated substantive discussions with any potential targets[110]. - The company has the option to extend the period to consummate an initial Business Combination up to nine times, each by an additional one-month period, until April 28, 2024[118]. - The company may utilize up to $1,500,000 in loans convertible into units of the post-business combination entity at a price of $10.00 per unit[129]. - The company believes it will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of a Business Combination or one year from the filing date[131]. - The company has incurred and expects to continue incurring significant costs in pursuit of financing and acquisition plans[131]. Shareholder Actions and Accounting - A total of 4,076,118 Public Shares were rendered for redemption during the extraordinary general meeting held on July 27, 2023[119]. - The company accounts for ordinary shares subject to possible redemption at a redemption value of $10.50 per share as of June 30, 2023[142]. - There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2023[151]. - The company does not expect the total amount of unrecognized tax benefits to materially change over the next twelve months[153]. - Management does not believe that any recently issued accounting standards would have a material effect on the company's financial statements[155]. Accounting Firm and Changes - The company appointed MaloneBailey, LLP as its new independent registered public accounting firm effective April 27, 2023, replacing Marcum LLP[117]. - The company has no off-balance sheet financing arrangements as of June 30, 2023[133].

IPO and Financial Proceeds - The Company completed its IPO on April 28, 2022, raising gross proceeds of $80.5 million from the sale of 8,050,000 units at $10.00 per unit[100]. - The Company incurred total transaction costs of $5,117,607 related to the IPO, including $1,610,000 in underwriting fees and $2,817,500 in deferred underwriting fees[111]. - The underwriters received a cash underwriting discount of $0.20 per Public Unit, totaling $1,610,000, and a deferred fee of approximately $2,817,500 upon the completion of a business combination[121]. Financial Position - As of March 31, 2023, the Trust Account held $83,563,893 in money market funds, primarily invested in U.S. Treasury Securities[112]. - As of March 31, 2023, the Company had cash of $5,169 and working capital of $55,966, with no amounts outstanding under any Working Capital Loans[115]. - As of March 31, 2023, the company has no off-balance sheet financing arrangements or obligations[118]. - The company has not experienced losses on its cash account and believes it is not exposed to significant credit risk as of March 31, 2023[130]. Business Operations and Strategy - The Company has not engaged in any operations or generated revenues to date, with activities focused on preparing for the IPO and identifying a target for a Business Combination[107]. - The Company plans to use funds held outside the Trust Account primarily for identifying and evaluating target businesses and performing due diligence[113]. - The Company has not selected any Business Combination target and has not initiated substantive discussions with any potential targets[98]. - The Company expects to incur significant costs in pursuit of its acquisition plans and does not anticipate generating operating revenues until after completing a Business Combination[107]. - The company does not anticipate needing to raise additional funds to meet operational expenditures prior to its initial Business Combination[117]. Management and Governance - The Company appointed I-Fa Chang as the sole director and CEO on March 17, 2023, following the resignation of all previous directors and officers[103]. Tax and Compliance - There were no unrecognized tax benefits or amounts accrued for interest and penalties as of March 31, 2023[136]. - The company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense, with no amounts accrued as of March 31, 2023[139]. - Management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months[138]. - The company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from reporting requirements[123].